What is Nektar Therapeutics share price today?

Nektar Therapeutics (NKTR) share price today is {{live_price}}.

Can Indians buy Nektar Therapeutics shares?

Yes, Indians can invest in the Nektar Therapeutics (NKTR) from India. With INDmoney, you can buy Nektar Therapeutics at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Nektar Therapeutics at zero transaction cost.

How can I buy Nektar Therapeutics shares from India?

It is very easy to buy Nektar Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Nektar Therapeutics be purchased?

Yes, you can buy fractional shares of Nektar Therapeutics with INDmoney app.

What are the documents required to start investing in Nektar Therapeutics stocks?

To start investing in Nektar Therapeutics, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Nektar Therapeutics

Today’s highest price of Nektar Therapeutics (NKTR) is {{1_rba_end}}. Today’s lowest price of Nektar Therapeutics (NKTR) is {{1_rba_st}}.

What is today's market capitalisation of Nektar Therapeutics

Today's market capitalisation of Nektar Therapeutics NKTR is 244.8M

What is the 52 Week High and Low Range of Nektar Therapeutics

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Nektar Therapeutics is down from its 52 Week High?

Nektar Therapeutics (NKTR) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Nektar Therapeutics is up from its 52 Week low?

Nektar Therapeutics (NKTR) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Nektar Therapeutics?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Nektar Therapeutics

Mr. Howard W. Robin is the current Chief Executive Officer (CEO) of Nektar Therapeutics.

Home>
US Stocks>
Nektar Therapeutics

Nektar Therapeutics (NKTR)

$1.3

-0.03

(-2.26%)▲

Market is closed - opens 7 PM, 04 Oct 2024

Performance

$1.26
$1.33
$1.30
3.07%
Downside
Day's Volatility :5.26%
Upside
2.26%
$0.41
$1.93
$1.30
68.26%
Downside
52 Weeks Volatility :78.6%
Upside
32.57%

Returns

Period	Nektar Therapeutics	Sector (Health Care)	Index (Russel 2000)
3 Months	0.78%	5.7%	0.0%
6 Months	-1.52%	6.7%	0.0%
1 Year	145.84%	18.4%	0.0%
3 Years	-92.82%	20.8%	-20.2%

Highlights

Market Capitalization	244.8M
Book Value	$0.43
Earnings Per Share (EPS)	-0.9
PEG Ratio	3.22
Wall Street Target Price	2.65

Profit Margin	-190.09%
Operating Margin TTM	-155.33%

Return On Assets TTM	-20.16%
Return On Equity TTM	-128.02%

Revenue TTM	93.2M
Revenue Per Share TTM	0.48
Quarterly Revenue Growth YOY	14.6%
Gross Profit TTM	70.4M
EBITDA	-128.7M
Diluted Eps TTM	-0.9
Quarterly Earnings Growth YOY	0.0

EPS Estimate Current Year	-0.84
EPS Estimate Next Year	-0.68
EPS Estimate Current Quarter	-0.2
EPS Estimate Next Quarter	-0.21

Analyst Recommendation

Hold

0%Buy

55%Hold

44%Sell

Based on 9 Wall street analysts offering stock ratings for Nektar Therapeutics(by analysts ranked 0 to 5 stars)

Based on 9 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 103.85%

Current $1.30

Target $2.65

Company Financials

	FY18	Y/Y Change
Revenue	1.2B	↑ 287.81%
Net Income	681.3M	↓ 804.62%
Net Profit Margin	57.09%	↑ 88.51%

	FY19	Y/Y Change
Revenue	114.6M	↓ 90.4%
Net Income	-440.7M	↓ 164.68%
Net Profit Margin	-384.47%	↓ 441.56%

	FY20	Y/Y Change
Revenue	152.9M	↑ 33.41%
Net Income	-444.4M	↑ 0.86%
Net Profit Margin	-290.65%	↑ 93.82%

	FY21	Y/Y Change
Revenue	101.9M	↓ 33.36%
Net Income	-523.8M	↑ 17.86%
Net Profit Margin	-514.03%	↓ 223.38%

	FY22	Y/Y Change
Revenue	92.1M	↓ 9.67%
Net Income	-368.2M	↓ 29.71%
Net Profit Margin	-399.98%	↑ 114.05%

	FY23	Y/Y Change
Revenue	90.1M	↓ 2.1%
Net Income	-276.1M	↓ 25.03%
Net Profit Margin	-306.31%	↑ 93.67%

	Q1 FY23	Q/Q Change
Revenue	21.6M	↓ 1.95%
Net Income	-137.0M	↑ 129.56%
Net Profit Margin	-634.52%	↓ 363.49%

	Q2 FY23	Q/Q Change
Revenue	20.5M	↓ 5.07%
Net Income	-51.1M	↓ 62.69%
Net Profit Margin	-249.39%	↑ 385.13%

	Q3 FY23	Q/Q Change
Revenue	24.1M	↑ 17.78%
Net Income	-45.8M	↓ 10.34%
Net Profit Margin	-189.85%	↑ 59.54%

	Q4 FY23	Q/Q Change
Revenue	23.9M	↓ 1.07%
Net Income	-42.1M	↓ 8.2%
Net Profit Margin	-176.17%	↑ 13.68%

	Q1 FY24	Q/Q Change
Revenue	21.6M	↓ 9.4%
Net Income	-36.8M	↓ 12.54%
Net Profit Margin	-170.07%	↑ 6.1%

	Q2 FY24	Q/Q Change
Revenue	23.5M	↑ 8.55%
Net Income	-52.4M	↑ 42.28%
Net Profit Margin	-222.93%	↓ 52.86%

	FY18	Y/Y Change
Total Assets	2.2B	↑ 322.54%
Total Liabilities	432.6M	↑ 2.75%

	FY19	Y/Y Change
Total Assets	2.0B	↓ 8.04%
Total Liabilities	572.0M	↑ 32.22%

	FY20	Y/Y Change
Total Assets	1.5B	↓ 22.18%
Total Liabilities	461.5M	↓ 19.32%

	FY21	Y/Y Change
Total Assets	1.1B	↓ 27.4%
Total Liabilities	437.7M	↓ 5.16%

	FY22	Y/Y Change
Total Assets	710.6M	↓ 36.39%
Total Liabilities	344.0M	↓ 21.41%

	FY23	Y/Y Change
Total Assets	398.0M	↓ 43.99%
Total Liabilities	267.0M	↓ 22.36%

	Q1 FY23	Q/Q Change
Total Assets	561.7M	↓ 20.95%
Total Liabilities	320.9M	↓ 6.71%

	Q2 FY23	Q/Q Change
Total Assets	494.3M	↓ 12.01%
Total Liabilities	297.3M	↓ 7.34%

	Q3 FY23	Q/Q Change
Total Assets	442.2M	↓ 10.53%
Total Liabilities	282.9M	↓ 4.86%

	Q4 FY23	Q/Q Change
Total Assets	398.0M	↓ 10.0%
Total Liabilities	267.0M	↓ 5.6%

	Q1 FY24	Q/Q Change
Total Assets	396.0M	↓ 0.51%
Total Liabilities	269.3M	↑ 0.85%

	Q2 FY24	Q/Q Change
Total Assets	343.3M	↓ 13.3%
Total Liabilities	263.6M	↓ 2.1%

	FY18	Y/Y Change
Operating Cash Flow	718.2M	↓ 993.15%
Investing Cash Flow	-1.4B	↑ 4689.95%
Financing Cash Flow	852.0M	↑ 1466.37%

	FY19	Y/Y Change
Operating Cash Flow	-328.7M	↓ 145.76%
Investing Cash Flow	206.9M	↓ 114.99%
Financing Cash Flow	23.4M	↓ 97.26%

	FY20	Y/Y Change
Operating Cash Flow	-313.3M	↓ 4.68%
Investing Cash Flow	496.2M	↑ 139.85%
Financing Cash Flow	-80.4M	↓ 444.05%

	FY21	Y/Y Change
Operating Cash Flow	-412.7M	↑ 31.72%
Investing Cash Flow	202.8M	↓ 59.14%
Financing Cash Flow	36.2M	↓ 145.1%

	FY22	Y/Y Change
Operating Cash Flow	-304.0M	↓ 26.33%
Investing Cash Flow	365.8M	↑ 80.41%
Financing Cash Flow	1.5M	↓ 95.84%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-51.9M	↓ 10.03%
Investing Cash Flow	40.6M	↑ 1.46%
Financing Cash Flow	18.0K	↓ 82.52%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-51.5M	↓ 0.76%
Investing Cash Flow	25.2M	↓ 38.0%
Financing Cash Flow	18.0K	↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Nektar Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Nektar Therapeutics	4.84%	-1.52%	145.84%	-92.82%	-93.15%
Regeneron Pharmaceuticals, Inc.	-13.97%	8.28%	24.49%	82.67%	258.6%
Novo Nordisk A/s	-14.46%	-7.16%	29.25%	137.43%	348.48%
Alnylam Pharmaceuticals, Inc.	6.47%	77.93%	59.32%	38.21%	249.95%
Vertex Pharmaceuticals Incorporated	-5.23%	12.26%	28.5%	155.67%	163.05%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Nektar Therapeutics	NA	NA	3.22	-0.84	-1.28	-0.2	NA	0.43
Regeneron Pharmaceuticals, Inc.	27.55	27.55	1.42	45.05	0.17	0.08	NA	261.41
Novo Nordisk A/s	38.7	38.7	1.75	3.41	0.89	0.23	0.01	25.24
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-2.49	-15.01	0.02	NA	-0.02
Vertex Pharmaceuticals Incorporated	32.84	NA	0.55	0.32	-0.03	0.13	NA	57.26

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Nektar Therapeutics	Hold	$244.8M	-93.15%	NA	-190.09%
Regeneron Pharmaceuticals, Inc.	Buy	$114.7B	258.6%	27.55	32.04%
Novo Nordisk A/s	Buy	$518.0B	348.48%	38.7	34.84%
Alnylam Pharmaceuticals, Inc.	Buy	$34.9B	249.95%	NA	-3.11%
Vertex Pharmaceuticals Incorporated	Buy	$119.3B	163.05%	32.84	-4.74%

Insights on Nektar Therapeutics

Increasing Revenue
Revenue is up for the last 2 quarters, 21.63M → 23.48M (in $), with an average increase of 7.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -36.80M → -52.36M (in $), with an average decrease of 42.3% per quarter
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.2% return, outperforming this stock by 131.0%